Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial.

Only one principal muscle group was treated per participant, which does not reflect real-world clinical practice where multiple muscles are often injected. The study duration was relatively short (12 weeks), which may have been insufficient to detect changes in active functional goals. There was no independent rater for the Modified Ashworth Scale, relying instead on trained assessors. The lack of dose-response relationship suggests that higher doses did not yield proportionally better tone reduction outcomes.

The study was conducted in conformance with Good Clinical Practices and included an Independent Drug Reconstitutor to maintain blinding. The text does not explicitly list specific funding sources or author conflicts of interest in the provided sentences, but notes it was a registrational study for FDA approval.

Do not interpret the significant reduction in muscle tone as evidence that the treatment improves active hand function. The study found no significant difference in active goal attainment compared to occupational therapy alone, and the functional outcomes were primarily limited to passive measures like splint tolerance.